Telephone: 416-340-6821; FAX: 416-340-3126;
Version of Record online: 27 DEC 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 19, Issue 1, pages 36–48, January 2013
How to Cite
Rabie, R., Mumtaz, K. and Renner, E. L. (2013), Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: A systematic review and meta-analysis. Liver Transpl, 19: 36–48. doi: 10.1002/lt.23516
Eberhard L. Renner has served as a member of advisory boards for Astellas, Novartis, Roche, and Vertex; as a member of the scientific committee for the SUSTAIN multicenter clinical trial (Novartis); and as a speaker for Novartis. He has also received grant support from Novartis Canada and Roche Canada.
This work was supported by an unrestricted grant to Eberhard L. Renner from Novartis Canada.
- Issue online: 27 DEC 2012
- Version of Record online: 27 DEC 2012
- Accepted manuscript online: 23 JUL 2012 06:26AM EST
- Manuscript Accepted: 10 JUL 2012
- Manuscript Received: 1 APR 2012
- 22009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. http://www.srtr.org/annual_reports/2010/ar_archives. htm. Accessed July 2012.
- 11ReViS-TC Study Group. Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011; 92: 334–340.
- 13Truven Health Analytics. Micromedex 2.0. http://www.micromedex.com/index.html. Accessed July 2012.
- 14http://www.ohri.ca/programs/clinical_ epidemiology/oxford.htm. Accessed July 2012., , , , , , . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
- 16Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: 18-month report [abstract]. Hepatology 2006; 44( suppl 1): 189A., , , , , , et al.
- 20Baseline, donor, and on-treatment predictors of sustained virologic response in patients treated for recurrent hepatitis C following orthotopic liver transplant: subanalysis of the PROTECT study [abstract]. Hepatology 2010; 52( suppl 1): 754A., , , , , , et al.
- 26Is the primary immunosuppressive drug (cyclosporine or tacrolimus) playing a role on the response to antiviral treatment for post-transplant HCV recurrence [abstract]? Liver Transpl 2011; 17( suppl 1): S97., , , , , et al.
- 28Interaction between cyclosporine and recipient IL-28B RS12979860 C>T genetic polymorphisms in the achievement of sustained viral response for recurrent hepatitis C [abstract]. J Hepatol 2012; 56( suppl 2): S37., , , , , et al.
- 33Early virological response and absence of diabetes are associated with sustained virological response to hepatitis C treatment after liver transplantation in patients with cyclosporine A based immunosuppression [abstract]. Hepatology 2008; 48( suppl 1): 581A., , , , , , et al.
- 35IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol; doi:10.1111/j.1440-1746.2012.07129.x., , , , , , et al.
- 38Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology; doi:10.1002/hep.25831., , , , , , et al.